Current Oncology,
Год журнала:
2023,
Номер
31(1), С. 145 - 167
Опубликована: Дек. 26, 2023
The
prevalence
of
breast
cancer
amongst
older
adults
in
Canada
is
increasing.
This
patient
population
faces
unique
challenges
the
management
cancer,
as
often
have
distinct
biological,
psychosocial,
and
treatment-related
considerations.
paper
presents
an
expert
consensus
Canadian
treatment
landscape,
focusing
on
key
considerations
for
optimizing
selection
systemic
therapy
advanced
adults.
aims
to
provide
evidence-based
recommendations
practical
guidance
healthcare
professionals
involved
care
with
cancer.
By
recognizing
addressing
specific
needs
adults,
providers
can
optimize
outcomes
improve
overall
quality
this
population.
British Journal of Cancer,
Год журнала:
2023,
Номер
129(5), С. 852 - 860
Опубликована: Июль 19, 2023
The
Ibrance®
Patient
Program
was
established
to
provide
access
palbociclib
for
UK
National
Health
Service
(NHS)
patients
with
metastatic
breast
cancer
(MBC),
pending
a
funding
decision.Non-interventional
cohort
study
involving
retrospective
medical
record
review
of
commenced
on
between
April
and
December
2017
at
eight
centres.
Primary
outcomes
included
clinicopathological
characteristics,
treatment
patterns,
clinical
selected
adverse
events.Overall,
191
were
identified,
median
age
57.0
years
(range
24.3-90.9);
30%
diagnosed
de
novo
MBC;
72%
received
first-line
10%
as
≥
second-line
treatment.
Median
progression-free
survival
(95%
CI)
22.8
months
(16.5-not
reached
[NR])
in
first-line;
NR
7.8
(6.8-NR)
(median
follow-up:
24
months).
overall
(OS)
the
cohort;
OS
rate
74.2%
(67.1-81.9%)
82.1%
(72.6-92.8%)
55.0%
(37.0-81.8%)
second-line.
Forty-seven
per
cent
developed
grade
3-4
neutropenia;
3%
febrile
neutropenia.This
supports
effectiveness
demonstrates
benefit
early
schemes
that
bridge
gap
regulatory
approval
NHS
new
medicines.Clinical
trial:
ClinicalTrial.gov:NCT03921866.
Geburtshilfe und Frauenheilkunde,
Год журнала:
2024,
Номер
84(09), С. 813 - 836
Опубликована: Сен. 1, 2024
Abstract
Endocrine-based
combination
therapy
with
an
inhibitor
of
the
cyclin-dependent
kinases
4
and
6
(CDK4/6
inhibitors)
is
currently
first-line
choice
for
patients
hormone
receptor-positive
(HR+)
human
epidermal
growth
factor
receptor
2-negative
(HER2−),
locally
advanced
or
metastatic
breast
cancer
(mBC).
The
efficacy
safety
treatment
palbociclib,
first
CDK4/6
approved
this
indication,
have
been
confirmed
in
large
randomized
controlled
clinical
trials
(RCTs)
strictly
defined
patient
cohorts.
Since
then,
many
relevant
questions
about
inhibition
palbociclib
mBC
investigated
RCTs
real-world
studies.
Based
on
evidence,
widely
used
practice
since
years
because
its
good
tolerability.
aim
review
to
summarize
findings
from
RWE
considering
clinically
aspects
such
as
safety,
tolerability,
quality
life
a
focus
specific
characteristics.
A
critical
discussion
overall
evidence
endocrine-based
can
contribute
support
decisions
daily
practice.
Breast Cancer Research and Treatment,
Год журнала:
2024,
Номер
208(2), С. 263 - 273
Опубликована: Июнь 26, 2024
To
compare
CDK4/6
inhibitor
(CDK4/6i)
with
endocrine
therapy
(ET)
in
the
first-
versus
second-line
setting
for
treatment
of
hormone
receptor
positive
(HR+),
HER2
negative,
metastatic
breast
cancer
(MBC)
using
real-world
evidence.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Фев. 1, 2024
Abstract
Background
Limited
data
are
available
regarding
the
real-world
effectiveness
and
safety
of
Cyclin
Dependent
Kinase
4/6
inhibitor
(CDK4/6i)
(palbociclib/ribociclib)
just
as
a
first-line
treatment
for
patients
with
hormone
receptor-positive/human
epidermal
growth
factor
receptor
2-negative
(HR+/HER2‒)
metastatic
breast
cancer
(MBC).
Objective
To
assess
whether
clinical
or
demographic
characteristics
limit
access
to
first
line
CDK4/6i
in
practice
Autonomous
Community
Andalusia
(Spain)
between
November
2017,
April
2020.
In
addition,
will
be
described
an
exploratory
analysis.
Methods
Physicians
from
12
centers
abstracted
characteristics,
outcome
women
HR+/HER2-
MBC
receiving
not
addition
hormonal
setting
3:1
proportion.
Kaplan–Meier
analysis
estimated
progression-free
rates
(PFRs)
survival
(SRs).
Results
A
total
212
were
included,
whom
175
(82.5%)
group
37
(17.5%)
non-CDK4/6i
(control
group).
CDK
4/6i
treated
younger
(p
=
0.0011),
biopsies
disease
done
more
frequently
0.0454),
multiple
metastases,
differences
relation
time
diagnosis
0.0304).
The
benefit
rate
(CBR)
was
82.3%
67.8%
control
group.
Median
progression
event
death
(PFS)
20.4
months
(95%CI
15.6–28)
12.1
7.9-not
reached)
Conclusions
Younger
patients,
metastases
CDK4/6i.
Clinical & Translational Oncology,
Год журнала:
2024,
Номер
unknown
Опубликована: Июнь 3, 2024
Abstract
Background
Limited
data
are
available
regarding
the
real-world
effectiveness
and
safety
of
Cyclin
Dependent
Kinase
4/6
inhibitor
(CDK4/6i)
(palbociclib/ribociclib)
just
as
a
first-line
treatment
for
patients
with
hormone
receptor-positive/human
epidermal
growth
factor
receptor
2-negative
(HR
+
/HER2‒)
metastatic
breast
cancer
(MBC).
Objective
To
assess
whether
clinical
or
demographic
characteristics
limit
access
to
CDK4/6i
in
practice
Autonomous
Community
Andalusia
(Spain)
between
November
2017
April
2020.
In
addition,
will
be
described
an
exploratory
analysis.
Methods
Physicians
from
12
centers
participated
selecting
characteristics,
treatment,
outcome
women
HR
/HER2-
MBC
treated
without
addition
hormonal
setting,
3:1
proportion.
Kaplan–Meier
analysis
estimated
progression-free
rates
(PFRs)
survival
(SRs).
Results
A
total
212
were
included,
whom
175
(82.5%)
group
37
(17.5%)
non-CDK4/6i
(control
group).
Patients
CDK
4/6i
younger
(p
=
0.0011),
biopsies
site
at
moment
relapse
most
commonly
performed
0.0454),
had
multiple
sites
0.0025).
The
benefit
rate
(CBR)
was
82.3%
67.8%
control
group.
Median
time
progression
event
death
(PFS)
20.4
months
(95%CI
15.6–28)
12.1
7.9–not
reached)
Conclusions
Younger
patients,
disease
more
frequently
our
daily
practice.
ESMO Open,
Год журнала:
2024,
Номер
9(11), С. 103965 - 103965
Опубликована: Окт. 31, 2024
Highlights•Older
population
represents
∼50%-60%
of
newly
diagnosed
cancer
patients.•This
is
at
higher
risk
anticancer
drug
toxicity
due
to
comorbidities
and
age-related
physiological
changes.•Understanding
pharmacology
risks
associated
with
age
can
prevent
severe
toxicities
in
older
patients.AbstractThe
the
patients
cancer.
Due
pathological
aging
increased
presence
frailty
factors,
this
serious
from
drugs
and,
consequently,
often
under-treated.
Despite
complexity
these
treatments,
a
good
knowledge
potentially
risky
situations
limit
emergence
lethal
population.
This
review
focuses
on
optimizing
systemic
oncology
treatments
for
patients,
emphasizing
unique
characteristics
each
therapeutic
class
necessity
precautionary
approach
vulnerable
population.Graphical
abstract
Meditsinskiy sovet = Medical Council,
Год журнала:
2023,
Номер
11, С. 150 - 157
Опубликована: Июль 30, 2023
The
development
and
introduction
of
cyclin-dependent
kinases
4/6
(CDK4/6)
inhibitors
into
clinical
practice
is
one
the
main
achievements
over
last
10
years
in
treatment
metastatic
breast
cancer.
All
randomized
trials
demonstrated
clinically
significant
efficacy
endocrine
therapy
plus
CDK4/6
first-
second-line
for
hormone-dependent
Her2-negative
Three
drugs
are
currently
approved
this
indication:
palbociclib,
ribociclib,
abemaciclib.
Despite
some
differences
chemical,
biological
pharmacological
properties,
as
well
a
range
incongruities
between
patient
populations
enrolled
studies
on
various
firstline
therapy,
all
showed
completely
comparable
improvement
progression-free
survival
with
hazard
ratio
0.5
regardless
previous
treatments.
Further
traceability
results
accumulation
real-world
experience
allowed
to
identify
potential
difference
not
only
overall
toxicity
profiles,
which
characteristic
each
drugs,
but
also
safety
use
patients
an
older
age
group.
As
aged
75
rarely
trials,
obtained
cannot
be
unequivocally
extrapolated
population,
decisive
factor
determining
value
unselected
population.
article
considers
case
reports
palbociclib
first-line
cancer
severe
comorbidities.
Current Oncology,
Год журнала:
2023,
Номер
31(1), С. 145 - 167
Опубликована: Дек. 26, 2023
The
prevalence
of
breast
cancer
amongst
older
adults
in
Canada
is
increasing.
This
patient
population
faces
unique
challenges
the
management
cancer,
as
often
have
distinct
biological,
psychosocial,
and
treatment-related
considerations.
paper
presents
an
expert
consensus
Canadian
treatment
landscape,
focusing
on
key
considerations
for
optimizing
selection
systemic
therapy
advanced
adults.
aims
to
provide
evidence-based
recommendations
practical
guidance
healthcare
professionals
involved
care
with
cancer.
By
recognizing
addressing
specific
needs
adults,
providers
can
optimize
outcomes
improve
overall
quality
this
population.
